SPRUCE BIOSCIENCES NOW ENROLLING TRIALS FOR ADULT PATIENTS LIVING WITH CLASSIC CAH

Clinical management of classic CAH is a balance between reducing excessive doses of glucocorticoids and reducing adrenal androgen levels. Investigational drug tildacerfont (once-daily treatment) from Spruce Biosciences has the potential to reduce androgen levels and address CAH symptom control such that steroid dosing could be reduced.
​
Click here to learn more details about the studies.

Visit the trial website to see if you qualify to enroll in the studies: www.CAHstudy.com.